Sino Biopharmaceutical (HKG:1177) obtained approval for marketing for Rivastigmine Transdermal Patch from the National Medical Products Administration of China, a Wednesday Hong Kong bourse filing said.
Trading under the name Debaitai, the patch is for the treatment of symptoms of mild-to-moderate Alzheimer's disease, a neurodegenerative condition with severe onset and progressive impairment, and a major cause of senile dementia.
Rivastigmine transdermal patch can supply a sustained and stable release of drug over a longer period, even for the patients who can not take oral medicines.
Price (HKD): $3.43, Change: $-0.030, Percent Change: -0.87%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。